It's all about sales, page-61

First 61 Last

Share
Profile

Follow
Designated survivor

200 Posts.

47

24/09/18

11:03

Post #: 35794931
Share

Originally posted by easylover ↑

For me enough has been said about this stock. Time for me to continue my travels...

So I will wrap this up.

I believe it to be terminal, but that is only my opinion. When I see the entire leadership team turn over twice in as many years suggests to me there are much greater issues than poor revenue reciepts.

How this organisation was ever valued at $1 is beyond my understanding and with hindsight it’s impossible to understand how they could forecast such high sales numbers.

But besides all the issues the company has faced and all the money that has been wasted. If you have a product the market wants then then they will buy it. It really is that simple.

This company is based in prime manufacturing country. Surabaya is the second largest city in Indonesia, but yet they have failed to take advantage of this. Currently they have 20 customers of any worth?

2 years in Bali, plus another 2 years in java and still only selling a third of what they need to reach a cash neutral position tells me the market isn’t ready for this product. 4 years is an incredible amount of time to build sales pipelines.

This company needs 60k pallets to break even per month, currently it’s selling a third of that. To reach a cash flow positive position it needs to sell more than that?

There is something wrong here, not sure on how to pin point it, except to say this company can’t seem to generate the sales it needs to be profitable. So the issue must be wrapped up in there somewhere, perhaps it’s time to question the technology or even ask what was the analysis prior to the float on market acceptance of this product? They operate in a high volume fast pace environment. But can’t find the volume and can’t get the uptake?

Nothing more to be said on this stock. I hope investors will see a profit on their investment. I hope it does turn around.

Expand

Upon reflection i think that this was a very incisive post and that its content remains answered.

RAN Price at posting: 5.4¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Emerald & Azure score Digger & Dealer awards

TNC

True North increases silver metal at QLD's Vero deposit by 20%

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Revolutionary inverter technology leads the clean energy charge

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Bitcoin: Current State of Play & Where to Next | Swyftx

HZR

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

TKM

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

NEU

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

There are more pages in this discussion • 8 more messages in this thread...

First 61 Last

Add RAN (ASX) to my watchlist

(20min delay)
Last 0.6¢		Change 0.000(0.00%)		Mkt cap ! $5.635M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

It's all about sales, page-61

Emerald & Azure score Digger & Dealer awards

True North increases silver metal at QLD's Vero deposit by 20%

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Revolutionary inverter technology leads the clean energy charge

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Bitcoin: Current State of Play & Where to Next | Swyftx

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Featured News

Featured News

It's all about sales, page-61

Top Stories

Emerald & Azure score Digger & Dealer awards

True North increases silver metal at QLD's Vero deposit by 20%

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Revolutionary inverter technology leads the clean energy charge

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Bitcoin: Current State of Play & Where to Next | Swyftx

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Featured News

Featured News